Based on the Bausch + Lomb Corp stock forecast from 3 analysts, the average analyst target price for Bausch + Lomb Corp is CAD 25.57 over the next 12 months. Bausch + Lomb Corp’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Bausch + Lomb Corp is Very Bullish, which is based on 14 positive signals and 1 negative signals. At the last closing, Bausch + Lomb Corp’s stock price was CAD 25.61. Bausch + Lomb Corp’s stock price has changed by -2.70% over the past week, -6.40% over the past month and +22.13% over the last year.
No recent analyst target price found for Bausch + Lomb Corp
No recent average analyst rating found for Bausch + Lomb Corp
Company Overview Bausch + Lomb Corp
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc. Read Less
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceut...Read More
Frequently Asked Questions About Bausch + Lomb Corp (BLCO:CA) Stock
Based on ratings from 3 analysts Bausch + Lomb Corp's stock is Buy . Stock Target Advisor's fundamental analysis is Very Bullish. The stock has 2 buy, sell and 5 hold ratings.
Unfortunately we do not have enough data on BLCO:CA's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for BLCO:CA is CAD 25.57 over the next 12 months. The maximum analyst target price is CAD 27.5 while the minimum anlayst target price is CAD 20.
BLCO:CA stock's Price/Earning ratio is 817.67.
Our analysis grades BLCO:CA stock's Price / Earning ratio at A+. This means that BLCO:CA stock's Price/Earning ratio is above 0% of the stocks in the Medical Instruments & Supplies sector in the TSX exchange.
Based on this BLCO:CA may be undervalued for its sector.
The last closing price of BLCO:CA's stock was CAD 25.61.
The most recent market capitalization for BLCO:CA is CAD 10.32B.
Based on targets from 3 analysts, the average taret price for BLCO:CA is projected at CAD 25.57 over the next 12 months.
This means that BLCO:CA's stock price may go down by -0.15% over the next 12 months.
We can't find any ETFs which contains Bausch + Lomb Corp's stock.
As per our most recent records Bausch + Lomb Corp has 13,000 Employees.
Bausch + Lomb Corp's registered address is 520 Applewood Crescent, Vaughan, ON, Canada, L4K 4B4.
You can get more information about it from Bausch + Lomb Corp's website at https://www.bausch.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low debt
The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
Underpriced on free cash flow basis
The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
Underpriced compared to earnings
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Frequently Asked Questions About Bausch + Lomb Corp (BLCO:CA) Stock
Based on ratings from 3 analysts Bausch + Lomb Corp's stock is Buy . Stock Target Advisor's fundamental analysis is Very Bullish. The stock has 2 buy, sell and 5 hold ratings.
Unfortunately we do not have enough data on BLCO:CA's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for BLCO:CA is CAD 25.57 over the next 12 months. The maximum analyst target price is CAD 27.5 while the minimum anlayst target price is CAD 20.
BLCO:CA stock's Price/Earning ratio is 817.67.
Our analysis grades BLCO:CA stock's Price / Earning ratio at A+. This means that BLCO:CA stock's Price/Earning ratio is above 0% of the stocks in the Medical Instruments & Supplies sector in the TSX exchange.
Based on this BLCO:CA may be undervalued for its sector.
The last closing price of BLCO:CA's stock was CAD 25.61.
The most recent market capitalization for BLCO:CA is CAD 10.32B.
Based on targets from 3 analysts, the average taret price for BLCO:CA is projected at CAD 25.57 over the next 12 months.
This means that BLCO:CA's stock price may go down by -0.15% over the next 12 months.
We can't find any ETFs which contains Bausch + Lomb Corp's stock.
As per our most recent records Bausch + Lomb Corp has 13,000 Employees.
Bausch + Lomb Corp's registered address is 520 Applewood Crescent, Vaughan, ON, Canada, L4K 4B4.
You can get more information about it from Bausch + Lomb Corp's website at https://www.bausch.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for BLCO:CA !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
